Zacks Investment Research lowered shares of Corvus Pharmaceuticals (NASDAQ:CRVS) from a hold rating to a sell rating in a research note issued to investors on Tuesday morning, Zacks.com reports.

According to Zacks, “Corvus Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of immuno-oncology therapies to harness the immune system to attack cancer cells. Its products include CPI-444, Adenosine production inhibitor, Adenosine A2B antagonist and Interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. Corvus Pharmaceuticals, Inc. is based in Burlingame, California. “

Other equities research analysts have also issued research reports about the stock. ValuEngine lowered shares of Corvus Pharmaceuticals from a buy rating to a hold rating in a research note on Friday, December 21st. Wedbush cut their target price on shares of Corvus Pharmaceuticals from $19.00 to $11.00 and set an outperform rating on the stock in a research note on Wednesday, March 13th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. Corvus Pharmaceuticals presently has a consensus rating of Hold and a consensus price target of $11.94.

Shares of Corvus Pharmaceuticals stock opened at $3.95 on Tuesday. Corvus Pharmaceuticals has a 1 year low of $3.22 and a 1 year high of $13.91.

Corvus Pharmaceuticals (NASDAQ:CRVS) last issued its earnings results on Thursday, March 7th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.10. As a group, equities research analysts forecast that Corvus Pharmaceuticals will post -1.66 EPS for the current year.

Several large investors have recently made changes to their positions in CRVS. Raymond James Trust N.A. bought a new stake in shares of Corvus Pharmaceuticals during the 1st quarter valued at about $53,000. Paloma Partners Management Co bought a new stake in shares of Corvus Pharmaceuticals during the 4th quarter valued at about $58,000. Rhumbline Advisers grew its position in shares of Corvus Pharmaceuticals by 44.1% during the 4th quarter. Rhumbline Advisers now owns 18,203 shares of the company’s stock valued at $67,000 after buying an additional 5,570 shares during the last quarter. Prudential Financial Inc. grew its position in shares of Corvus Pharmaceuticals by 15.0% during the 4th quarter. Prudential Financial Inc. now owns 21,545 shares of the company’s stock valued at $79,000 after buying an additional 2,805 shares during the last quarter. Finally, Citadel Advisors LLC bought a new stake in shares of Corvus Pharmaceuticals during the 3rd quarter valued at about $182,000. 85.71% of the stock is owned by institutional investors and hedge funds.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint.

Featured Story: Technical Analysis of Stocks, How Can It Help

Get a free copy of the Zacks research report on Corvus Pharmaceuticals (CRVS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.